Association of Cannabinoid Specialists
Erik Smith, MD, currently serves as Physician Consultant and Medical Director at Veriheal, and has held various positions within the healthcare sector, including Medical Director at VeriNew and Independent Health Consultant at Erik C. Smith, MD, LLC. Active membership in several professional organizations such as The American Academy of Anti-Aging Medicine, the Association of Cannabinoid Specialists, and the American Board of Obstetrics and Gynecology reflects a commitment to ongoing professional development. Erik Smith completed a Graduate Certificate in Medical Cannabis Business and Industry at the University of the Sciences in Philadelphia, complemented by a residency in Obstetrics and Gynecology at Albert Einstein Medical Center and a medical degree from Howard University. Additional educational background includes a Bachelor of Science degree in Pharmacology and Toxicology from the University of the Sciences in Philadelphia.
This person is not in any teams
This person is not in any offices
Association of Cannabinoid Specialists
The Association of Cannabis Specialists ensures the highest standards in the practice of cannabis medicine, safeguards patient care with clinical best practices, and interfaces with other stakeholders in the cannabis community. We believe that patients are uniquely vulnerable and have very different needs than recreational users. We provide evidence and experience-based education for patients, cannabis clinicians, referring clinicians, and lawmakers to help them understand cannabis medicine and make informed decisions. We are a political organization striving to implement best practices in the laws and regulations at the federal, state, and international levels. Our Core Values: • Patients are a vulnerable group who deserve the highest standard of medical care and products. • Recreational use is not the same as medical use. These groups have different goals and needs and must be addressed separately. • Prohibition of cannabis is a major public health hazard that has failed to decrease drug use and has led to unsupportable consequences. • Cannabis is medicine. It should be regulated like other medications and be available by prescription including in botanical form. • Cannabis products should not make unsubstantiated medical claims. Products should be required to meet strict standards of safety, bioavailability, and efficacy. • Dispensaries should operate like pharmacies. They should provide products that are safe and effective. They should not provide medical advice to patients. They should not contradict patients’ clinicians’ orders.